Dr. James Del Rosso (JDR Dermatology Research, Las Vegas, Nevada, USA, and President-Elect American Acne & Rosacea Society) discusses the efficacy and safety results from the CAMP-1 and CAMP-2 studies, highlighting their role in supporting the recent FDA approval cantharidin solution (0.7%) for treatment of molluscum contagiosum. He also examines who benefits most from the […]

Molluscum contagiosum, a common skin infection caused by a poxvirus (molluscum contagiosum virus), usually resulting in benign, mild skin disease characterized by lesions appearing anywhere on the body. In this interview, Dr. James Del Rosso (JDR Dermatology Research, Las Vegas, Nevada, USA, and President-Elect American Acne & Rosacea Society) shares insights into molluscum contagiosum, and […]

The phase III SUNSHINE and SUNRISE were two identical, multicentre, randomized, placebo-controlled, double-blind phase 3 trials performed in 219 primary sites across 40 countries. With few therapeutic options available for patients with moderate-to-severe hidradenitis suppurativa (HS), Dr Afsaneh Alavi (Mayo Clinic College of Medicine, Rochester, MN, USA) joins touchDERMATOLOGY to discuss the limitations of current […]

Explore some of the key insights from EADV 2023: Prof. Thierry Passeron illuminates pigmentary disorders breakthroughs, Dr Raj Chovatiya unveils atopic dermatitis innovations, Prof. Leonardo Marini sheds light on aesthetic medicine developments, and Prof. Dedee Murrell reveals treatment progress exciting clinical trials and key discoveries in blistering and autoimmune diseases. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

GUIDE is a phase 3b randomized, parallel-group, double-blind trial investigating guselkumab for the treatment of moderate-to-severe psoriasis (NCT03818035). We were delighted to speak with Prof. Knut Schäkel (University Hospital Heidelberg, Germany) to discuss the clinical data already supporting GUS from GUIDE 1 and 2, and the rationale, methodology and findings from GUIDE part 3, which were presented at EADV. The abstract 'Treatment-free period of more than 1 year in guselkumab super responders with short disease duration of psoriasis: withdrawal data from the GUIDE trial' (Abstract N°: 2042) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What were the aims, design and eligibility criteria of the Phase 3b GUIDE trial? (0:16) What data from GUIDE 1 and 2 already supports early intervention with GUS? (1:28) Could you describe the rationale and methodology of GUIDE part 3? (2:19) What were the clinical endpoints and how well were these achieved? (3:10) What significance do these findings have in terms of maintenance of response following GUS withdrawal? (4:06) Disclosures: Knut Schäkel has been an advisor and/ or received speakers' honoraria and/ or received grants and/ or participated in clinical trials of the following companies: AbbVie, Almirall, Antabio, Boehringer Ingelheim, Celgene, Eli Lily, Galderma, Janssen-Cilag GmbH, LEO Pharma, Novartis, Pfizer and UCB Pharma. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.  Click here for more content on psoriasis & for further EADV 2023 highlights visit here.

Aesthetic medicine research has grown dramatically in recent years driven by technological advances, and novel treatments for skin diseases and cosmetic procedures. In this interview touchDERMATOLOGY spoke with Prof. Leonardo Marini (The Skin Doctors’ Center of Trieste, Italy) to discuss the latest developments and future directions in aesthetic medicine, and most recently the combined treatments across different dermatological indications. The presentation 'Combination treatments in aesthetic medicine.' (Session ID D4T06.4) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What recent advancements in aesthetic medicine have been the most promising? (0:22) What is the rationale for combining treatments in aesthetic medicine? (1:13) What do you see as the future direction of aesthetic medicine? (2:57) Disclosures: Leonardo Marini has nothing to disclose in relation to this video interview. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

The POETYK PSO long term extension (LTE) study investigated the efficacy and safety of deucravacitinib at 3 years in patients with plaque psoriasis (NCT04036435). touchDERMATOLOGY were delighted to speak with Dr. Leon. Kircik around the mechanism of action of deucravacitinib, the clinical data supporting its use in clinical practice, and the long term efficacy and safety data from the POETYK PSO LTE. This information is provided solely by Touch Medical Media and is independent of any sponsorship or affiliation with the European Academy of Dermatology & Venereology (EADV). Questions What is the mechanism of action of deucravacitinib? (0:21) What clinical evidence already supports the use of deucravacitinib? (0:41) What were the findings from the POETYK PSO long-term extension trial? (1:25) How will these insights optimise the use of deucravacitinib in plaque psoriasis? (2:10) In which patients is deucravacitinib most beneficial? (2:43) Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Non-melanoma skin cancer (NMSC) is responsible for a higher worldwide mortality rate compared to melanoma, a more severe type of skin cancer. A comprehensive analysis of global skin cancer incidence and mortality assessed global skin cancer epidemiology, emphasizing incidence, mortality, risk profiles, and dermatologist density’s impact. touchDERMATOLOGY caught up with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the key outcomes and the likely impact the findings will have on clinical practice. The abstract 'A comprehensive analysis of global skin cancer incidence and mortality with a focus on dermatologist density and population risk factors' (Abstract N°: P1519) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What is the global burden of non-melanoma skin cancer? (0:11) What were the key outcomes from your study of WHO International Agency for Research on Cancer? (0:38) What impact will these findings have on clinical practice? (1:58) Disclosures: Thierry Passeron has been a consultant for Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma; received grant/research support from Abbvie, Almirall, BMS, Celgene, Incyte, Isocell, LEO Pharma, Lilly; and has received honorarium from Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Touch Medical Media coverage of data presented at EADV 2023: The phase 2b study evaluating upadacitinib (RINVOQ®) in adults with non-segmental vitiligo achieved the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index, with no new safety signals identified. touchDERMATOLOGY caught up with Prof. Thierry Passeron (University Hospital of Nice, Nice, […]